GZR101 vs Insulin glargine (Basaglar)

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Type 2 Diabetes

Shared mechanism: Insulin receptor (basal) · full Type 2 Diabetes pipeline

GZR101

Developed by Gan & Lee Pharmaceuticals

Phase 2 in Type 2 Diabetespeptide
Partial signal

NCT06199505 · Phase 2 · completed

The study used randomization and an active comparator, but it was open-label and had a surrogate primary endpoint—change in HbA1c rather than a hard clinical outcome. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.

Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.

Next expected readout: February 2027 · NCT07387003 (registry estimate)

Reported efficacy

Change in HbA1c (Baseline to week 16): Change in HbA1c from baseline to week 16: Part A GZR101 once-daily -1.56% vs IDegAsp once-daily -1.31% (difference -0.24%); Part B GZR101+aspart once-daily -1.64% and twice-daily -1.68% vs IDegAsp twice-daily -1.59% (differences -0.06% and -0.09%). (met)

Result source: NCT06199505

Insulin glargine (Basaglar)

Marketed by Eli Lilly and partners

Approved in Type 2 Diabetespeptide
Partial signal

NCT01421459 · Phase 3 · completed

The study was randomized, triple-blind, and active-controlled, with 759 participants, but its primary endpoint was HbA1c, a laboratory surrogate rather than a hard clinical outcome. The prespecified non-inferiority comparison was met: the 95% confidence interval for the treatment difference remained below the +0.4% margin.

Reported efficacy

Change From Baseline in Hemoglobin A1c (HbA1c) (LY2963016 to Lantus®) (Baseline, Week 24): Change From Baseline in Hemoglobin A1c (HbA1c) (LY2963016 to Lantus®) (Baseline, Week 24): LY2963016 -1.27 Percentage of HbA1c (Standard Error 0.043) vs Lantus® -1.23 Percentage of HbA1c (Standard Error 0.062) (met)

Result source: NCT03338010

Results for Type 2 Diabetes

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointGZR101Insulin glargine (Basaglar)
HbA1c, change-1.6% vs -1.3%avs IDegAsp once-dailywk 16NCT06199505
2 other results
-1.3% vs -1.3%vs Lantuswk 24 · n 369NCT01421459
9 other results
  • -1.3% vs -1.2% wk 24 · n 226 · Phase 3 · primary NCT02302716
  • -1.3% vs -1.2% wk 24 · n 334 · Phase 3 · primary NCT03338010
  • -1.3% vs -1.3% wk 16 · n 369 · Phase 3 · secondary NCT01421459
  • -1.1% vs -1.1% wk 12 · n 369 · Phase 3 · secondary NCT01421459
  • -1.3% vs -1.4% wk 20 · n 369 · Phase 3 · secondary NCT01421459
  • -0.9% vs -0.9% wk 8 · n 369 · Phase 3 · secondary NCT01421459
  • -1.3% vs -1.4% wk 24 · n 369 · Phase 3 · secondary NCT01421459
  • -1.3% vs -1.2% wk 24 · n 334 · Phase 3 · secondary NCT03338010
  • -0.5% vs -0.5% wk 4 · n 369 · Phase 3 · secondary NCT01421459
Body weight, change (kg)—Not reported1.9 vs 2.2vs Lantuswk 24 · n 370NCT01421459
7 other results
  • 2.3 vs 1.7 wk 24 · n 229 · Phase 3 · secondary NCT02302716
  • 1.1 vs 1.2 wk 24 · n 334 · Phase 3 · secondary NCT03338010
  • 1.7 vs 2.2 wk 20 · n 370 · Phase 3 · secondary NCT01421459
  • 1.6 vs 1.9 wk 16 · n 370 · Phase 3 · secondary NCT01421459
  • 1.3 vs 1.4 wk 12 · n 370 · Phase 3 · secondary NCT01421459
  • 1.0 vs 1.2 wk 8 · n 370 · Phase 3 · secondary NCT01421459
  • 0.3 vs 0.5 wk 4 · n 370 · Phase 3 · secondary NCT01421459
HbA1c below 7%—Not reported43.7% vs 44.9%vs Lantus®wk 24 · n 334NCT03338010
Fasting plasma glucose, change—Not reported—Not reported
3-point MACE (% with event)—Not reported—Not reported

HbA1c, change

GZR101
-1.6% vs -1.3%avs IDegAsp once-dailywk 16NCT06199505
2 other results
Insulin glargine (Basaglar)
-1.3% vs -1.3%vs Lantuswk 24 · n 369NCT01421459
9 other results
  • -1.3% vs -1.2% wk 24 · n 226 · Phase 3 · primary NCT02302716
  • -1.3% vs -1.2% wk 24 · n 334 · Phase 3 · primary NCT03338010
  • -1.3% vs -1.3% wk 16 · n 369 · Phase 3 · secondary NCT01421459
  • -1.1% vs -1.1% wk 12 · n 369 · Phase 3 · secondary NCT01421459
  • -1.3% vs -1.4% wk 20 · n 369 · Phase 3 · secondary NCT01421459
  • -0.9% vs -0.9% wk 8 · n 369 · Phase 3 · secondary NCT01421459
  • -1.3% vs -1.4% wk 24 · n 369 · Phase 3 · secondary NCT01421459
  • -1.3% vs -1.2% wk 24 · n 334 · Phase 3 · secondary NCT03338010
  • -0.5% vs -0.5% wk 4 · n 369 · Phase 3 · secondary NCT01421459

Body weight, change (kg)

GZR101
—Not reported
Insulin glargine (Basaglar)
1.9 vs 2.2vs Lantuswk 24 · n 370NCT01421459
7 other results
  • 2.3 vs 1.7 wk 24 · n 229 · Phase 3 · secondary NCT02302716
  • 1.1 vs 1.2 wk 24 · n 334 · Phase 3 · secondary NCT03338010
  • 1.7 vs 2.2 wk 20 · n 370 · Phase 3 · secondary NCT01421459
  • 1.6 vs 1.9 wk 16 · n 370 · Phase 3 · secondary NCT01421459
  • 1.3 vs 1.4 wk 12 · n 370 · Phase 3 · secondary NCT01421459
  • 1.0 vs 1.2 wk 8 · n 370 · Phase 3 · secondary NCT01421459
  • 0.3 vs 0.5 wk 4 · n 370 · Phase 3 · secondary NCT01421459

HbA1c below 7%

GZR101
—Not reported
Insulin glargine (Basaglar)
43.7% vs 44.9%vs Lantus®wk 24 · n 334NCT03338010

Fasting plasma glucose, change

GZR101
—Not reported
Insulin glargine (Basaglar)
—Not reported

3-point MACE (% with event)

GZR101
—Not reported
Insulin glargine (Basaglar)
—Not reported
  1. a From a reviewed publication or company release; CT.gov has no posted result for this endpoint.
  2. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  3. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. GZR101: 0 of 4 rows · Insulin glargine (Basaglar): 4 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricGZR101Insulin glargine (Basaglar)
Dropout rate—
11.9%a
NCT01421459 · Phase 3 · combination · Type 2 Diabetes · phase 3
show 3 more results
7.6%
NCT02302716 · Phase 3 · combination · Type 2 Diabetes · phase 3
6.4%
NCT03338010 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
28.3%
NCT04153981 · Phase 4 · registry result, not featured evidence
Discontinued due to AEs—
1.6%a
NCT01421459 · Phase 3 · combination · Type 2 Diabetes · phase 3
show 3 more results
0.4%
NCT02302716 · Phase 3 · combination · Type 2 Diabetes · phase 3
0.8%
NCT03338010 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
—
NCT04153981 · Phase 4 · registry result, not featured evidence
Serious AEs—
4%a
NCT01421459 · Phase 3 · combination · Type 2 Diabetes · phase 3
show 3 more results
4%
NCT02302716 · Phase 3 · combination · Type 2 Diabetes · phase 3
7.8%
NCT03338010 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
0.4%
NCT04153981 · Phase 4 · registry result, not featured evidence
Most frequent reported AEs—
a
nasopharyngitis 5.6%
upper respiratory tract infection 5.1%
abnormal weight gain 2.7%
NCT01421459 · Phase 3 · combination · Type 2 Diabetes · phase 3
show 3 more results
nasopharyngitis 7.2%
upper respiratory tract infection 4%
weight increased 3.2%
NCT02302716 · Phase 3 · combination · Type 2 Diabetes · phase 3
upper respiratory tract infection 20.3%
hypertension 5.6%
injection site pain 4.2%
NCT03338010 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
anaemia 1.9%
cough 0.4%
hyperglycaemia 0.4%
NCT04153981 · Phase 4 · registry result, not featured evidence

Notes

  1. aPopulation comparability has not been reviewed for 1 of these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Insulin glargine (Basaglar)

Weight 0.292 vs 0.526 Lantus kg @ 4wk
absolute change · kg
NCT01421459 · Phase 3 · combination · Type 2 Diabetes · phase 3
show 7 more results
0.999 vs 1.152 Lantus kg @ 8wk
NCT01421459 · Phase 3 · combination · Type 2 Diabetes · phase 3
1.271 vs 1.44 Lantus kg @ 12wk
NCT01421459 · Phase 3 · combination · Type 2 Diabetes · phase 3
1.55 vs 1.918 Lantus kg @ 16wk
NCT01421459 · Phase 3 · combination · Type 2 Diabetes · phase 3
1.734 vs 2.234 Lantus kg @ 20wk
NCT01421459 · Phase 3 · combination · Type 2 Diabetes · phase 3
1.914 vs 2.175 Lantus kg @ 24wk
NCT01421459 · Phase 3 · combination · Type 2 Diabetes · phase 3
2.3 vs 1.7 LANTUS® kg @ 24wk
NCT02302716 · Phase 3 · combination · Type 2 Diabetes · phase 3
1.1 vs 1.2 Lantus® kg @ 24wk
NCT03338010 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
HbA1c Less Than 7% 43.7% (n=334) vs 44.9% (n=158) Lantus® @ 24wk
responder rate · % of participants
NCT03338010 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
HbA1c Less Than or Equal to 6.5 23.4% (n=334) vs 16.5% (n=158) Lantus® @ 24wk
responder rate · % of participants
NCT03338010 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
Weight -0.5 kg @ 24wk
absolute change · kg
No placebo or comparator arm
NCT04153981 · Phase 4 · registry result, not featured evidence
HbA1c -0.641% (n=259) @ 12wk
absolute change · percentage points
No placebo or comparator arm
NCT04153981 · Phase 4 · registry result, not featured evidence
show 1 more result
-0.86% (n=259) @ 24wk
NCT04153981 · Phase 4 · registry result, not featured evidence
SMBG 7-point Change mg/dL -38.7 mg @ 24wk
absolute change · mg
No placebo or comparator arm
Blood glucose concentration before breakfast
NCT04153981 · Phase 4 · registry result, not featured evidence

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: GZR101's landscape · Insulin glargine (Basaglar)'s landscape